live attenuated vaccines

live attenuated vaccines

Vaccines containing live viruses and other organisms that have been rendered safe by chemical or other means. They include vaccines against measles, mumps and rubella (M-M-R II, Priorix), rubella alone (Erevax), yellow fever (Arilvax), chickenpox (Varilrix), tuberculosis (BCH vaccine) and poliomyelitis.
References in periodicals archive ?
Coupled with the recent European Medicine Agencys (EMA) decision to allow the production of live attenuated vaccines in cell-lines like EB66, this strongly supports the choice of EB66 as a modern cell technology platform for vaccine development and manufacturing.
It has involved the extensive use of both the live attenuated vaccines that can revert to a wild type phenotype, and inactivated polio vaccines (IPV) whose production in the main currently requires the growth of very large amounts of virulent wild type poliovirus," they explain, noting that the vaccines are therefore a possible source for re-emergence of poliomyelitis following eradication (PLoS Pathog.
Since the 1960s, live attenuated vaccines have been developed against polio (oral, 1962), measles (1963), rubella (1969), chickenpox (1995) and a number of other bacterial or viral pathogens.
Although these IgG biologicals will clear the infants' systems after several months of life (generally by 8 months), another concern is for how their presence in the early months impacts neonatal vaccination, specifically live attenuated vaccines such as MMR (measles, mumps and rubella), BCG for tuberculosis, oral polio, rotavirus vaccine, and the intranasal influenza vaccine.
Because of increased efficacy and fewer adverse reactions, the vaccine containing the Enders-Edmonston vaccine strain replaced previous vaccines: inactivated Edmonston vaccine (available in the United States from 1963 through 1967), live attenuated vaccines containing the Edmonston B (available in the United States from 1963 through 1975), and Schwarz strain (available in the United States from 1965 through 1976).
The incidence of YF was dramatically reduced following the development of live attenuated vaccines in the 1930s (3).
Avoid all travel-specific live attenuated vaccines.
Thus, this strategy potentially allows for the generic development of live attenuated vaccines against many new viral pathogens, with reduced costs and the potential single dose induction of long-term immunity.
The study suggests that regulation of live attenuated vaccines for all species needs to take into account the real potential for vaccine viruses to combine.
Two types of live attenuated vaccines have been used worldwide for the control of infectious laryngotraeheitis virus (ILTV): 1) chicken embryo origin (CEO) vaccines; and 2) tissue culture origin vaccines (TCO).
Recently, interest in the use of live attenuated vaccines against bacterial pathogens in fish has increased (Temprano et al.
In addition, recombinant influenza viruses with impaired NS1 function might represent efficient live attenuated vaccines against influenza.